Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsPayablesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cyclerion Therapeutics (CYCN) Retained Earnings (2019 - 2025)

Cyclerion Therapeutics has reported Retained Earnings over the past 7 years, most recently at -$270.2 million for Q3 2025.

  • Quarterly results put Retained Earnings at -$270.2 million for Q3 2025, changed N/A from a year ago — trailing twelve months through Sep 2025 was -$270.2 million (changed N/A YoY), and the annual figure for FY2024 was -$267.5 million, down 1.16%.
  • Retained Earnings for Q3 2025 was -$270.2 million at Cyclerion Therapeutics, roughly flat from -$269.2 million in the prior quarter.
  • Over the last five years, Retained Earnings for CYCN hit a ceiling of -$18000.0 in Q3 2023 and a floor of -$270.3 million in Q2 2023.
  • Median Retained Earnings over the past 5 years was -$209.7 million (2021), compared with a mean of -$153.1 million.
  • Biggest five-year swings in Retained Earnings: soared 99.99% in 2022 and later crashed 1399684.21% in 2024.
  • Cyclerion Therapeutics' Retained Earnings stood at -$215.1 million in 2021, then soared by 99.99% to -$20000.0 in 2022, then plummeted by 1321985.0% to -$264.4 million in 2023, then fell by 1.16% to -$267.5 million in 2024, then fell by 1.02% to -$270.2 million in 2025.
  • The last three reported values for Retained Earnings were -$270.2 million (Q3 2025), -$269.2 million (Q2 2025), and -$268.9 million (Q1 2025) per Business Quant data.